Mutación BRAF V600E en pacientes con cáncer de tiroides. Fundación Clínica Valle del Lili: una serie de casos

  • Guillermo Edinson Guzmán Fundación Valle del Lili, Cali, Colombia
  • Luz Ángela Casas Fundación Valle del Lili, Cali, Colombia
  • Julian David Orrego Celestino Universidad del Valle
  • Juliana Escobar Fundación Valle del Lili, Cali, Colombia
  • Lisa Rodríguez Fundación Valle del Lili, Cali, Colombia
  • Veline Martínez Fundación Valle del Lili, Cali, Colombia

Resumen

Objetivo: Describir las caracterticas clicas y los hallazgos histopatolicos de los pacientes con diagntico de ccer de tiroides y estudio de la mutaci del Gen BRAF V600E.
Modos: Estudio descriptivo, retrospectivo, con informaci obtenida de las historias clicas de los pacientes con diagntico de ccer de tiroides atendidos durante 2014 y 2105 en la Fundaci Clica Valle del Lili con estudio para la mutaci del gen BRAF V600E.
Resultados: De los 344 pacientes con diagntico de ccer de tiroides durante los as 2014 y 2015, se les realizestudio de la mutaci BRAF V600E a 24. La edad promedio fue de 47 as, con predominio en mujeres (87,5%), fueron positivos para la mutaci 66% de los pacientes. En relaci a las caracterticas histopatolicas, el 95,8% de los casos correspondn a ccer papilar de tiroides, la mayor de la variedad clica. Los pacientes con la mutaci BRAF V600E tenn mayor extensi extratiroidea, invasi linfica, invasi vascular y compromiso ganglionar, pero no se encontrrelaci con respecto a tama tumoral, multicentralidad, bilateralidad, tiroiditis de Hashimoto o presencia de mettasis.
Conclusi: Este es el primer estudio en Colombia, que describe las caracterticas clicas e histopatolicas de los pacientes con ccer de tiroides en relaci a la presencia de la mutacion del Gen BRAF.

Abstract
Objective: To describe the clinical and histopathological findings of patients diagnosed with thyroid cancer and BRAF V600E gene mutation study.
Methods: A descriptive, retrospective study, with information obtained from the medical records of patients diagnosed with thyroid cancer seen during 2014 and 2105 in the Fundacion Clica Valle del Lili with analysis of the BRAF V600E gene mutation.
Results: Of the 344 patients diagnosed with thyroid cancer during the years 2014 and 2015, underwent study of the BRAF V600E to 24. The average age was 47 years, with prevalence in women (87.5%) were positive for mutation 66% of patients. Regarding the histopathologic features, 95.8% of the cases werepapillary thyroid cancer, most classic variety. Patients with BRAF V600E mutation were more extrathyroid extension, lymphatic invasion, vascular invasion and nodal involvement, but no relationship was found with respect to tumor size, multicentrality, bilateralism, Hashimotos thyroiditis or presence of metastasis.
Conclusion: This is the first study in Colombia, describing the clinical and histopathologic of patients with thyroid cancer in relation to the presence of the BRAF gene mutation characteristics.-

##plugins.generic.usageStats.downloads##

##plugins.generic.usageStats.noStats##

Biografía del autor

##submission.authorWithAffiliation##

Mico Internista Endocrinogo, Profesor Clico asociado Universidad ICESI, Fundaci Clica Valle del Lili

##submission.authorWithAffiliation##

Mico Internista Endocrinogo, Profesor Clico asociado Universidad ICESI, Fundaci Clica Valle del Lili

##submission.authorWithAffiliation##

Mico Internista, Universidad del Valle

##submission.authorWithAffiliation##

Mico Patoga, PhD, Profesor asociado Universidad ICESI, Fundaci Clica Valle del Lili

##submission.authorWithAffiliation##

Mico Genetista, MSD, PhD, Fundaci Clica Valle del Lili

##submission.authorWithAffiliation##

Mico Internista, Profesor Clico asociado Universidad ICESI, Fundaci Clica Valle del Lili

Citas

1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26(1):1-133.
2. Pardo CC, Ricardo. Incidencia prevalencia y mortalidad de Cancer en Colombia 2007 a 2011.
3. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control. 2000;7(3):229-39.
4. Sun J, Zhang J, Lu J, Gao J, Ren X, Teng L, et al. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients. PLoS One. 2016;11(4): e0153319.
5. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92(11):4085-90.
6. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papil- lary thyroid carcinoma. Cancer Res. 2003;63(7):1454-7.
7. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245-62.
8. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015;33(1):42-50.
9. Peralta Gómez JA. Mutación BRAF V600E y su asociación con presencia de carcinoma de tiroides papilar en bacaf de pacientes con nódulo tiroideo. Biblioteca digital Universidad Nacional de Colombia 2015.
10. Edge SB BD, Compton CC, Fritz AG, Greene, FL TA. AJCC Cancer Staging Man- ual. 7th ed: Springer-Verlag; 2010.
11. Li C, Lee KC, Schneider EB, Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012;97(12):4559-70.
12. Asioli S, Erickson LA, Sebo TJ, Zhang J, Jin L, Thompson GB, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol. 2010;34(1):44-52.
13. Jin L, Chen E, Dong S, Cai Y, Zhang X, Zhou Y, et al. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 65 patients. Oncotarget. 2016.
14. Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore). 2012;91(5):274-86.
15. Fraser S, Go C, Aniss A, Sidhu S, Delbridge L, Learoyd D, et al. BRAF Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer. World J Surg. 2016.
16. Mariscal SJ, Rocio. Sastre, Julia. Aso, Sonsoles. Gonzales, Ariel. Estudio de mutaciones v600e del gen BRAF en el carcinoma papilar de tiroides. 2012.
Publicado
2017-03-21
##submission.howToCite##
GUZM?N, Guillermo Edinson et al. Mutaci BRAF V600E en pacientes con ccer de tiroides. Fundaci Clica Valle del Lili: una serie de casos. Revista Colombiana de Endocrinología, Diabetes & Metabolismo, [S.l.], v. 3, n. 3, p. 45-49, mar. 2017. ISSN 2389-9786. Disponible en: <http://revistaendocrino.org/index.php/rcedm/article/view/42>. Fecha de acceso: 16 feb. 2019
Sección
Casos Clínicos

##plugins.generic.recommendByAuthor.heading##